To determine whether HDAC6 inhibition is a viable therapeutic strategy for ovarian cancer, we measured the protein levels of HDACs 1, 2, and 6 in human ovarian cancer cell lines (Fig. 1A). Here, HDAC6 is linked to ovarian carcinoma.